My Fund

Loading your portfolio…

Checking your account and saved picks.

Choose a startup

Explore all 1120 companies in this selection. Research each company before making your pick.

Includes historical VC holdings. A listing does not confirm current ownership or startup stage.

VC tracking →

Showing 1–7 of 7 startups

Netic

Collecting history

Company website description

Netic’s AI-driven platform helps service enterprises boost revenue, engage customers, and scale growth with intelligent automation. See how our multi-channel engine empowers your business.

Founders Fund
netic.ai ↗
Research Netic

Tracking coverage

First reading saved. Waiting for a later comparable reading.

Momentum +1 · Collecting history
First reading saved. Waiting for a later comparable reading.Last reading:
Fundraising +2 · Awaiting data
No verified dated source evidence recorded.
New VC +3 · Awaiting data
No verified dated source evidence recorded.
Completed exit +10 · Awaiting data
Exit news coverage has not started.

Coverage describes public evidence. Points require a qualifying milestone after your pick.

Company website description

Netic’s AI-driven platform helps service enterprises boost revenue, engage customers, and scale growth with intelligent automation. See how our multi-channel engine empowers your business.

Visit netic.ai ↗Product description source ↗

Product source checked 31 Oct 2026

Tracked VC backing

A portfolio listing documents backing; its observation date is not an investment date.

Dated public activity

No dated funding or investment events recorded yet.

History is research context. Only qualifying milestones after your pick earn points.

Company and sources ↗

CX2

Limited coverage

Company website description

CX2 delivers spectrum dominance to the battlefield by providing AI-enabled hardware and software that see, disrupt, and defend the electromagnetic domain in contested environments.

Andreessen Horowitz
cx2.com ↗
Research CX2

Tracking coverage

Some source history is available; coverage remains limited.

Momentum +1 · Limited coverage
The latest public index does not report a rank for this company.Index checked:
Fundraising +2 · Awaiting data
No verified dated source evidence recorded.
New VC +3 · Awaiting data
No verified dated source evidence recorded.
Completed exit +10 · Awaiting data
Exit news coverage has not started.

Coverage describes public evidence. Points require a qualifying milestone after your pick.

Company website description

CX2 delivers spectrum dominance to the battlefield by providing AI-enabled hardware and software that see, disrupt, and defend the electromagnetic domain in contested environments.

Visit cx2.com ↗Product description source ↗

Product source checked 31 Oct 2026

Tracked VC backing

A portfolio listing documents backing; its observation date is not an investment date.

Dated public activity

No dated funding or investment events recorded yet.

History is research context. Only qualifying milestones after your pick earn points.

Company and sources ↗

Dyno Therapeutics

Limited coverage

Company website description

Building high-performance genetic technologies that transform patient lives.

Andreessen Horowitz
dynotx.com ↗
Research Dyno Therapeutics

Tracking coverage

Some source history is available; coverage remains limited.

Momentum +1 · Limited coverage
The latest public index does not report a rank for this company.Index checked:
Fundraising +2 · Awaiting data
No verified dated source evidence recorded.
New VC +3 · Awaiting data
No verified dated source evidence recorded.
Completed exit +10 · Awaiting data
Exit news coverage has not started.

Coverage describes public evidence. Points require a qualifying milestone after your pick.

Company website description

Building high-performance genetic technologies that transform patient lives.

Visit dynotx.com ↗Product description source ↗

Product source checked 31 Oct 2026

Tracked VC backing

A portfolio listing documents backing; its observation date is not an investment date.

Dated public activity

No dated funding or investment events recorded yet.

History is research context. Only qualifying milestones after your pick earn points.

Company and sources ↗

Kamau Therapeutics

Limited coverage

Company website description

Kamau Therapeutics is a clinical-stage gene correction company focused on developing curative, single-dose precision therapies for serious genetic diseases using high-efficiency targeted DNA integration.

Khosla Ventures
kamautx.com ↗
Research Kamau Therapeutics

Tracking coverage

Some source history is available; coverage remains limited.

Momentum +1 · Limited coverage
The latest public index does not report a rank for this company.Index checked:
Fundraising +2 · Awaiting data
No verified dated source evidence recorded.
New VC +3 · Awaiting data
No verified dated source evidence recorded.
Completed exit +10 · Awaiting data
Exit news coverage has not started.

Coverage describes public evidence. Points require a qualifying milestone after your pick.

Company website description

Kamau Therapeutics is a clinical-stage gene correction company focused on developing curative, single-dose precision therapies for serious genetic diseases using high-efficiency targeted DNA integration.

Visit kamautx.com ↗Product description source ↗

Product source checked 31 Oct 2026

Tracked VC backing

A portfolio listing documents backing; its observation date is not an investment date.

Dated public activity

No dated funding or investment events recorded yet.

History is research context. Only qualifying milestones after your pick earn points.

Company and sources ↗

Liberate Bio

Limited coverage

Company website description

Delivering genetic medicines that transcend liver-based limitations, liberating patients from disease

Khosla Ventures
liberatebio.com ↗
Research Liberate Bio

Tracking coverage

Some source history is available; coverage remains limited.

Momentum +1 · Limited coverage
The latest public index does not report a rank for this company.Index checked:
Fundraising +2 · Awaiting data
No verified dated source evidence recorded.
New VC +3 · Awaiting data
No verified dated source evidence recorded.
Completed exit +10 · Awaiting data
Exit news coverage has not started.

Coverage describes public evidence. Points require a qualifying milestone after your pick.

Company website description

Delivering genetic medicines that transcend liver-based limitations, liberating patients from disease

Visit liberatebio.com ↗Product description source ↗

Product source checked 31 Oct 2026

Tracked VC backing

A portfolio listing documents backing; its observation date is not an investment date.

Dated public activity

No dated funding or investment events recorded yet.

History is research context. Only qualifying milestones after your pick earn points.

Company and sources ↗

Moonwalk Biosciences

Limited coverage

Company website description

By deeply profiling and targeting the epigenetic code, Moonwalk aims to reprogram cells to their healthy state, fundamentally enabling a new approach to how therapies…

Khosla Ventures
moonwalk.bio ↗
Research Moonwalk Biosciences

Tracking coverage

Some source history is available; coverage remains limited.

Momentum +1 · Limited coverage
The latest public index does not report a rank for this company.Index checked:
Fundraising +2 · Awaiting data
No verified dated source evidence recorded.
New VC +3 · Awaiting data
No verified dated source evidence recorded.
Completed exit +10 · Awaiting data
Exit news coverage has not started.

Coverage describes public evidence. Points require a qualifying milestone after your pick.

Company website description

By deeply profiling and targeting the epigenetic code, Moonwalk aims to reprogram cells to their healthy state, fundamentally enabling a new approach to how therapies…

Visit moonwalk.bio ↗Product description source ↗

Product source checked 31 Oct 2026

Tracked VC backing

A portfolio listing documents backing; its observation date is not an investment date.

Dated public activity

No dated funding or investment events recorded yet.

History is research context. Only qualifying milestones after your pick earn points.

Company and sources ↗

Stylus Medicine

Limited coverage

Company website description

Stylus Medicine, Inc. is a biotechnology company dedicated to developing transformative in vivo genetic medicines.

Khosla Ventures
stylusmedicine.com ↗
Research Stylus Medicine

Tracking coverage

Some source history is available; coverage remains limited.

Momentum +1 · Limited coverage
The latest public index does not report a rank for this company.Index checked:
Fundraising +2 · Awaiting data
No verified dated source evidence recorded.
New VC +3 · Awaiting data
No verified dated source evidence recorded.
Completed exit +10 · Awaiting data
Exit news coverage has not started.

Coverage describes public evidence. Points require a qualifying milestone after your pick.

Company website description

Stylus Medicine, Inc. is a biotechnology company dedicated to developing transformative in vivo genetic medicines.

Visit stylusmedicine.com ↗Product description source ↗

Product source checked 31 Oct 2026

Tracked VC backing

A portfolio listing documents backing; its observation date is not an investment date.

Dated public activity

No dated funding or investment events recorded yet.

History is research context. Only qualifying milestones after your pick earn points.

Company and sources ↗
How it works

Pick up to 50 companies. Your picks are private to your account.

A new US fundraising disclosure (Form D) earns 2 points. A first investment announced by a tracked VC earns 3. Milestones must occur and be observed after your pick.

Measured growth earns 1 point once: the same RiseFinder composite score rises between dated observations after your pick, using one formula version. Where available, a supported public source metric can also qualify. Lower ranks are better; rising counts are better. A completed, dated IPO or acquisition earns 10 points once.

The composite score measures relative public signals on a 0–100 scale. It is not a company valuation. Coverage varies; companies without qualifying history wait for evidence.

Initial imports, old discoveries, follow-ons from existing backers, amendments, undated events and same-day events earn no points.

Points track verified milestones after your pick. They do not represent investment returns.